ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0785

Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity

Shivani Garg1, Betty Chewning2, Brad Astor3 and Christie M. Bartels3, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Pharmacy, Madison, WI, 3University of Wisconsin, School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2023

Keywords: Health Care, Measurement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: SLE – Treatment I: Renal

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to 5 mg/kg to limit toxicity per American Academy of Ophthalmologists (AAO) guidelines, increases lupus flare risk by 6-fold. Therefore, establishing effective reference ranges of HCQ blood levels with upper and lower bounds for efficacy may inform individualizing HCQ dosing to maximize efficacy and limit toxicity. While studies suggest various thresholds for therapeutic HCQ blood levels, none have offered a therapeutic range with upper and lower bounds for HCQ levels that predict minimum and maximum efficacy. Moreover, clinical interpretation of a threshold is difficult as it may not account for changes in patient-level factors such as weight and kidney function and fluctuations in HCQ blood levels over time. Thus, the objectives of this study were to: 1) examine the association between HCQ blood levels and high lupus disease activity (HDA) in a prospective SLE cohort; 2) define therapeutic thresholds of HCQ blood levels with upper and lower bounds for HCQ blood levels that predict maximum and minimum efficacy.

Methods: This study measured HCQ blood levels in unique SLE visits using liquid chromatography-tandem mass spectrometry. HCQ blood levels and SLE disease activity index (SLEDAI) scores were measured on the day of the visit for each patient. High lupus disease activity (HDA) was defined as SLEDAI scores of ≥6. We performed nonparametric spline regression analysis to identify HCQ blood levels cut-points associated with reduction in the odds of HDA. To identify an effective therapeutic range with lower and upper limits of HCQ blood levels that are associated with lower odds of HDA, we examined associations between HDA and every 50-100 ng/ml increase in HCQ blood levels starting at 100 ng/ml through 1500 ng/ml using univariable and multivariable logistic regression models. Factors that can affect HCQ levels, such as kidney function, HCQ dose and timing, were included in analyses.

Results: Among 158 SLE patients in whom HCQ blood levels were measured, 92% were women and 32% were of Black race or Hispanic ethnicity. HDA was noted in 18% of patients.

Using nonparametric spline regression models, we noted that HCQ blood levels, 750 and 1100 ng/ml, significantly reduced the odds of HDA (Figure 1A). HCQ blood levels < 700 & >1150 did not reduce the odds of HDA (Figure 1B & Table 1). Levels of 750 ng/ml lowered the lower odds of HDA by 76% (OR 0.24, p=0.016, Fig 1B & Table 1). A sustained reduction in the odds of HDA with HCQ blood levels was noted through 1000 ng/ml. Peak effects were noted at levels of 1100 ng/ml with a 90% reduction in the odds of HDA (Figure 1B. & Table 1). Figure 2. illustrates how these findings could guide clinicians to individualize HCQ dosing to achieve therapeutic blood levels to maximize efficacy, while balancing safety.

Conclusion: An effective therapeutic range of HCQ levels, 750-1100 ng/ml, significantly reduced the odds of high lupus disease activity by 76-90%. These findings could be guide clinicians to individualize HCQ dosing to maximize efficacy during routine lupus visits.

Supporting image 1

Table 1. Factors associated with high lupus disease activity (HDA defined as SLEDAI ≥6) using multivariable logistic regression, n=158

Supporting image 2

Figure 1. Effective range of HCQ levels associated with lower odds of high lupus disease
activity (HDA) using: A) spline and B) logistic regression analysis

Supporting image 3

Figure 2. Potential clinical application of therapeutic hydroxychloroquine blood level monitoring during routine clinic visits


Disclosures: S. Garg: None; B. Chewning: None; B. Astor: None; C. Bartels: Pfizer, 5.

To cite this abstract in AMA style:

Garg S, Chewning B, Astor B, Bartels C. Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/therapeutic-range-of-hydroxychloroquine-blood-levels-may-reduce-odds-of-high-lupus-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-range-of-hydroxychloroquine-blood-levels-may-reduce-odds-of-high-lupus-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology